SOURCE: International Stem Cell Corporation

International Stem Cell Corporation

January 07, 2015 08:30 ET

International Stem Cell Corporation to Present at Biotech Showcase™ 2015

CARLSBAD, CA--(Marketwired - January 07, 2015) - International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, announced today that the Company's Chief Financial Officer, Mr. Jay Novak, Chief Scientific Officer, Ruslan Semechkin Ph.D., and Executive Vice President, Simon Craw Ph.D. will attend the Biotech Showcase™ 2015 Conference being held in San Francisco, CA from January 12 through 14, 2015. Dr. Craw will present a corporate overview.

Details of presentation are as follows:

Event: Biotech Showcase™ 2015 Conference
Date: January 13, 2015
Time: 5:00 PM
Location: D - Powell (3rd Floor): Parc 55 Wyndham San Francisco Union Square Hotel
Webcast: http://edge.media-server.com/m/p/ofv8ayer

The Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies an opportunity to present to, and meet with, investors and pharmaceutical executives during the course of one of the industry's largest annual healthcare investor conferences. Now in its seventh year, Biotech Showcase is expected to attract upwards of 1,500 attendees. 

About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at www.internationalstemcell.com or http://companyblog.intlstemcell.com/

To receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0

Contact Information